| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Joëlle A Pasman, Karin J H Verweij, Zachary Gerring, Sven Stringer, Sandra Sanchez-Roige, Jorien L Treur, Abdel Abdellaoui, Michel G Nivard, Bart M L Baselmans, Jue-Sheng Ong, Hill F Ip, Matthijs D van der Zee, Meike Bartels, Felix R Day, Pierre Fontanillas, Sarah L Elson, Harriet de Wit, Lea K Davis, James MacKillop, Jaime L Derringer, Susan J T Branje, Catharina A Hartman, Andrew C Heath, Pol A C van Lier, Pamela A F Madden, Reedik Mägi, Wim Meeus, Grant W Montgomery, A J Oldehinkel, Zdenka Pausova, Josep A Ramos-Quiroga, Tomas Paus, Marta Ribases, Jaakko Kaprio, Marco P M Boks, Jordana T Bell, Tim D Spector, Joel Gelernter, Dorret I Boomsma, Nicholas G Martin, Stuart MacGregor, John R B Perry, Abraham A Palmer, Danielle Posthuma, Marcus R Munafò, Nathan A Gillespie, Eske M Derks, Jacqueline M Vin. Author Correction: GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nature neuroscience. vol 22. issue 7. 2021-02-03. PMID:31168101. |
several occurrences of the word 'schizophrenia' have been re-worded as 'liability to schizophrenia' or 'schizophrenia risk', including in the title, which should have been "gwas of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability," as well as in supplementary figures 1-10 and supplementary tables 7-10, to more accurately reflect the findings of the work. |
2021-02-03 |
2023-08-13 |
Not clear |
| Julie Schoevers, Judith E Leweke, F Markus Lewek. Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies. Current opinion in psychiatry. vol 33. issue 3. 2021-02-01. PMID:32073423. |
cannabidiol as a treatment option for schizophrenia: recent evidence and current studies. |
2021-02-01 |
2023-08-13 |
Not clear |
| Julie Schoevers, Judith E Leweke, F Markus Lewek. Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies. Current opinion in psychiatry. vol 33. issue 3. 2021-02-01. PMID:32073423. |
the most recent studies published or initiated in the last 18 months, investigating cannabidiol in the treatment of symptoms of schizophrenia and related conditions are summarized, including observed tolerability and reported side-effects. |
2021-02-01 |
2023-08-13 |
Not clear |
| Jennie E Ryan, Philip Veliz, Sean E McCabe, Sarah A Stoddard, Carol J Boy. Association of early onset of cannabis, cigarette, other drug use and schizophrenia or psychosis. Schizophrenia research. vol 215. 2021-01-18. PMID:31623965. |
association of early onset of cannabis, cigarette, other drug use and schizophrenia or psychosis. |
2021-01-18 |
2023-08-13 |
Not clear |
| Sinan Guloksuz, Lotta-Katrin Pries, Philippe Delespaul, Gunter Kenis, Jurjen J Luykx, Bochao D Lin, Alexander L Richards, Berna Akdede, Tolga Binbay, Vesile Altınyazar, Berna Yalınçetin, Güvem Gümüş-Akay, Burçin Cihan, Haldun Soygür, Halis Ulaş, EylemŞahin Cankurtaran, Semra Ulusoy Kaymak, Marina M Mihaljevic, Sanja Andric Petrovic, Tijana Mirjanic, Miguel Bernardo, Bibiana Cabrera, Julio Bobes, Pilar A Saiz, María Paz García-Portilla, Julio Sanjuan, Eduardo J Aguilar, José Luis Santos, Estela Jiménez-López, Manuel Arrojo, Angel Carracedo, Gonzalo López, Javier González-Peñas, Mara Parellada, Nadja P Maric, Cem Atbaşog Lu, Alp Ucok, Köksal Alptekin, Meram Can Saka, Celso Arango, Michael O'Donovan, Bart P F Rutten, Jim van O. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World psychiatry : official journal of the World Psychiatric Association (WPA). vol 18. issue 2. 2021-01-09. PMID:31059627. |
evidence was found for additive interaction of molecular genetic risk state for schizophrenia (binary mode of prs-scz above 75% of the control distribution) with the presence of lifetime regular cannabis use and exposure to early-life adversities (sexual abuse, emotional abuse, emotional neglect, and bullying), but not with the presence of hearing impairment, season of birth (winter birth), and exposure to physical abuse or physical neglect in childhood. |
2021-01-09 |
2023-08-13 |
Not clear |
| Julie Aamand Olesen, Christine Merrild Posselt, Chalotte Heinsvig Poulsen, Merete Nordentoft, Carsten Hjorthø. Cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls. Psychological medicine. vol 50. issue 3. 2020-12-31. PMID:30880659. |
cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls. |
2020-12-31 |
2023-08-13 |
Not clear |
| Julie Aamand Olesen, Christine Merrild Posselt, Chalotte Heinsvig Poulsen, Merete Nordentoft, Carsten Hjorthø. Cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls. Psychological medicine. vol 50. issue 3. 2020-12-31. PMID:30880659. |
we aimed to investigate whether cannabis use disorders (cud) would decrease the risk of incident disorders of the digestive organs, in people with schizophrenia and population controls. |
2020-12-31 |
2023-08-13 |
Not clear |
| Eleftheria Kopelli, Myrto Samara, Antonios Siargkas, Antonis Goulas, Georgios Papazisis, Michail Chourdaki. The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis. Psychiatry research. vol 291. 2020-12-14. PMID:32599446. |
the role of cannabidiol oil in schizophrenia treatment. |
2020-12-14 |
2023-08-13 |
Not clear |
| Eleftheria Kopelli, Myrto Samara, Antonios Siargkas, Antonis Goulas, Georgios Papazisis, Michail Chourdaki. The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis. Psychiatry research. vol 291. 2020-12-14. PMID:32599446. |
the purpose of the present meta-analysis was to assess the efficacy of cannabidiol (cbd) oil in patients with schizophrenia. |
2020-12-14 |
2023-08-13 |
Not clear |
| Tibor Stark, Martina Di Bartolomeo, Roberta Di Marco, Eva Drazanova, Chiara Bianca Maria Platania, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Claudio D'Addario, Lucie Kratka, Vladimir Pekarik, Fabiana Piscitelli, Zuzana Babinska, Julia Fedotova, Giovanni Giurdanella, Salvatore Salomone, Alexandra Sulcova, Claudio Bucolo, Carsten T Wotjak, Zenon Starcuk, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Mical. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochemical pharmacology. vol 177. 2020-12-07. PMID:32360362. |
altered dopamine d3 receptor gene expression in mam model of schizophrenia is reversed by peripubertal cannabidiol treatment. |
2020-12-07 |
2023-08-13 |
rat |
| Tibor Stark, Martina Di Bartolomeo, Roberta Di Marco, Eva Drazanova, Chiara Bianca Maria Platania, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Claudio D'Addario, Lucie Kratka, Vladimir Pekarik, Fabiana Piscitelli, Zuzana Babinska, Julia Fedotova, Giovanni Giurdanella, Salvatore Salomone, Alexandra Sulcova, Claudio Bucolo, Carsten T Wotjak, Zenon Starcuk, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Mical. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochemical pharmacology. vol 177. 2020-12-07. PMID:32360362. |
in summary, our results demonstrate that the mrna expression of both dopamine d2 and d3 receptors is altered in the mam model; however only the transcript levels of d3 are affected by cannabidiol treatment, likely suggesting that this gene might not only contribute to the schizophrenia symptoms but also represent an unexplored target for the antipsychotic activity of cannabidiol. |
2020-12-07 |
2023-08-13 |
rat |
| Naista Zhand, Roisin Osborne, Marika Stuyt, Anna Hatko, Laura Friberg, Amira Rouabhi, David Attwoo. Incidental finding of age and time disorientation in a clinical sample of patients with schizophrenia: Findings from a short term follow up survey regarding cannabis use. Psychiatry research. vol 290. 2020-12-07. PMID:32540587. |
incidental finding of age and time disorientation in a clinical sample of patients with schizophrenia: findings from a short term follow up survey regarding cannabis use. |
2020-12-07 |
2023-08-13 |
human |
| Naista Zhand, Roisin Osborne, Marika Stuyt, Anna Hatko, Laura Friberg, Amira Rouabhi, David Attwoo. Incidental finding of age and time disorientation in a clinical sample of patients with schizophrenia: Findings from a short term follow up survey regarding cannabis use. Psychiatry research. vol 290. 2020-12-07. PMID:32540587. |
the current article reports on an incidental finding from our survey study on patterns of cannabis use pre-post legalization in patients with schizophrenia. |
2020-12-07 |
2023-08-13 |
human |
| Ewa Kozela, Martyna Krawczyk, Tomasz Kos, Ana Juknat, Zvi Vogel, Piotr Popi. Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats. Molecular neurobiology. vol 57. issue 3. 2020-12-04. PMID:31823199. |
cannabidiol (cbd), a non-psychotropic cannabinoid, demonstrates antipsychotic-like and procognitive activities in humans and in animal models of schizophrenia. |
2020-12-04 |
2023-08-13 |
rat |
| Rosa Ayesa-Arriola, Víctor Ortíz-García de la Foz, Esther Setién-Suero, María Luz Ramírez-Bonilla, Paula Suárez-Pinilla, Jacqueline Mayoral-van Son, Javier Vázquez-Bourgon, María Juncal-Ruiz, Marcos Gómez-Revuelta, Diana Tordesillas-Gutiérrez, Benedicto Crespo-Facorr. Understanding sex differences in long-term outcomes after a first episode of psychosis. NPJ schizophrenia. vol 6. issue 1. 2020-11-25. PMID:33219222. |
existence of a schizophrenia diagnosis, and cannabis and alcohol consumption were more probable among men. |
2020-11-25 |
2023-08-13 |
Not clear |
| Rosa Ayesa-Arriola, Víctor Ortíz-García de la Foz, Esther Setién-Suero, María Luz Ramírez-Bonilla, Paula Suárez-Pinilla, Jacqueline Mayoral-van Son, Javier Vázquez-Bourgon, María Juncal-Ruiz, Marcos Gómez-Revuelta, Diana Tordesillas-Gutiérrez, Benedicto Crespo-Facorr. Understanding sex differences in long-term outcomes after a first episode of psychosis. NPJ schizophrenia. vol 6. issue 1. 2020-11-25. PMID:33219222. |
ten years later, more females continued living independently and had partners, while schizophrenia diagnoses and cannabis consumption continued to be more frequent among men. |
2020-11-25 |
2023-08-13 |
Not clear |
| Justine Renard, Walter J Rushlow, Steven R Laviolett. Effects of Adolescent THC Exposure on the Prefrontal GABAergic System: Implications for Schizophrenia-Related Psychopathology. Frontiers in psychiatry. vol 9. 2020-10-01. PMID:30013490. |
considerable clinical evidence supports the hypothesis that adolescent neurodevelopmental exposure to high levels of the principal psychoactive component in marijuana, -delta-9-tetrahydrocanabinol (thc), is associated with a high risk of developing psychiatric diseases, such as schizophrenia later in life. |
2020-10-01 |
2023-08-13 |
Not clear |
| Jegason P Diviant, Jacob M Vigil, Sarah S Stit. The Role of Cannabis within an Emerging Perspective on Schizophrenia. Medicines (Basel, Switzerland). vol 5. issue 3. 2020-10-01. PMID:30096776. |
the role of cannabis within an emerging perspective on schizophrenia. |
2020-10-01 |
2023-08-13 |
Not clear |
| Fernanda F Peres, Mariana C Diana, Raquel Levin, Mayra A Suiama, Valéria Almeida, Ana M Vendramini, Camila M Santos, Antônio W Zuardi, Jaime E C Hallak, José A Crippa, Vanessa C Abíli. Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia. Frontiers in pharmacology. vol 9. 2020-10-01. PMID:30186164. |
cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia. |
2020-10-01 |
2023-08-13 |
Not clear |
| Amber L Bahorik, Jack R Cornelius, Srihari S Bangalore, Christina E Newhill, Matcheri S Keshavan, Shaun M Eac. BRIEF REPORT: THE IMPACT OF ALCOHOL AND CANNABIS MISUSE ON COGNITION AMONG INDIVIDUALS WITH SCHIZOPHRENIA. Schizophrenia research. Cognition. vol 1. issue 3. 2020-09-30. PMID:25419516. |
brief report: the impact of alcohol and cannabis misuse on cognition among individuals with schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |